Kenvue Inc. (KVUE)
Consumer Staples · Personal Care Products · US stock · S&P 500 component
$18.91
▲ +0.24 (1.29%)
Fair valueFair
$24 +27.0% to fair value
$12fair band $17–$31$36
Day's range
$18.72 – $18.95
52-week range
$13.22 – $19.67
Red flags⚠ Dividend may be at risk
About Kenvue Inc.
Kenvue is a consumer health company that was separated from Johnson & Johnson. It makes everyday products for self care, skin health, baby care and oral care under familiar names such as Tylenol, Neutrogena, Aveeno, Listerine and Band-Aid. These goods reach shoppers through supermarkets, pharmacies, mass retailers and online stores around the world, and the company is organised into self care, skin health and beauty, and essential health divisions.
Kenvue earns revenue from consumer products that it supplies to retail partners. In the last twelve months sales came to $15.4 billion, and they grew by only 0.4% a year across the last three years. The operating margin is 17.1%, and the business earns a profit of 18% on the capital invested in it. It carries net debt of 0.1 times EBITDA. The company pays a dividend with a yield of 5.5%. On the site's X-Ray Score it receives 47 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $13.22 – $19.67Volume 27,692,800Daily, split-adjusted
Vitals
Market cap$36.4B
52-week range$13.22 – $19.67
Volume (last day)27,692,800
P/E (TTM)21.9
EBIT / EV yield7.2%
Free-cash-flow yield5.3%
Dividend yield5.5%
Revenue (TTM)$15.4B
Net income (TTM)$1.7B
Operating margin17.1%
Return on capital18.1%
Debt incl. leases$1.4B
Cash & securities$1.1B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$24model spread $23 – $25
Fair
+27.0% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $19
Undervalued < $17Fair $17 – $31Overvalued > $31
10-year DCF (market-scaled)
$24
Peer multiples
$21
Earnings power floor (not blended)
$12
Fundamentals-adjusted multiple
$27
Growth the price implies
6.0%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Weak business, fairly priced
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Consumer Staples peers. Open a lens to see the numbers behind it.
Valuation
Fair
65/100
Priced about in line with its sector.
See the numbers →
EBIT / EV yield7.2%
Free-cash-flow yield5.3%
Fair value vs price1.3×
Growth
Weak
25/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)0.4%
EPS growth (3y)-14.1%
Growth consistency40%
Profitability
Fair
52/100
Returns on capital are typical for its sector.
See the numbers →
Return on invested capital18.1%
Operating margin17.1%
Gross profitability33.5%
Financial health
Weak
46/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score6 / 9
Net debt / EBITDA0.1×
Interest cover6.2×
Dividends
Weak
32/100
Dividend is modest or less certain than peers.
See the numbers →
Dividend yield5.5%
Dividends vs free cash flow105%
Quarterly results: last 6 quarters
-3.9%
Mar '25
-4.0%
Jun '25
-3.5%
Sep '25
+3.2%
Dec '25
+4.5%
Mar '26
+3.0%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $4.0B, diluted EPS $0.24.
Compare with peers
PG PROCTER & GAMBLE Co55 EL Estee Lauder Companies...33Other Personal Care Products companies by X-Ray Score.
Fundamentals checklist
● 4 Good · ● 6 Average · ● 6 BadCash quality
Earnings backed by cashBad
Free-cash-flow yieldAverage
Risk models
Altman Z''Bad
Piotroski F-ScoreAverage
Growth
EPS growth (3y)Bad
Free-cash-flow growth (3y)Bad
Revenue growth (3y)Average
Growth consistencyBad
Balance sheet
Current ratioAverage
Net debt / EBITDAGood
Interest coverBad
Valuation
Fair value vs priceAverage
EBIT / EV yieldGood
Profitability
Return on invested capitalGood
Operating marginGood
Gross profitabilityAverage
Each check is graded against the company's sector, not a fixed number. Checklist score 50/100.
Financials
| FY22 | FY23 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $15.1B | $15.0B | $15.4B | $15.5B | $15.1B |
| Operating income | $2.9B | $2.7B | $2.5B | $1.8B | $2.4B |
| Net income | $2.1B | $2.1B | $1.7B | $1.0B | $1.5B |
| Operating cash flow | $334M | $2.5B | $3.2B | $1.8B | $2.2B |
| Operating margin | 19.4% | 17.9% | 16.3% | 11.9% | 16.0% |
| Free cash flow | $39M | $2.2B | $2.7B | $1.3B | $1.7B |
| Diluted EPS | $1.21 | $1.20 | $0.90 | $0.54 | $0.76 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 1 neutral · 3 bearish
Weekly
Strongly bullish
9 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
5 bullish · 1 neutral · 1 bearish
Moving averages (daily)
| SMA 10 | 17.91 | Bullish |
| EMA 10 | 18.08 | Bullish |
| SMA 20 | 17.78 | Bullish |
| EMA 20 | 17.95 | Bullish |
| SMA 50 | 18.19 | Bullish |
| EMA 50 | 18.05 | Bullish |
| SMA 100 | 18.22 | Bullish |
| EMA 100 | 18.01 | Bullish |
| SMA 200 | 17.61 | Bullish |
| EMA 200 | 17.88 | Bullish |
Oscillators (daily)
| RSI (14) | 69.14 | Neutral |
| MACD (12, 26) | 0.07 | Bullish |
| Momentum (12) | 7.08 | Bullish |
| Stochastic %K (14) | 98.04 | Bearish |
| Williams %R (14) | -1.96 | Bearish |
| CCI (20) | 306.0 | Bearish |
Pivot points (classic, last session)
S3 18.54 | S2 18.63 | S1 18.77 | Pivot 18.86 | R1 19.00 | R2 19.09 | R3 19.23 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
1.04 USD
Yield on today's price
5.52%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 21 Sep 2026 | 0.2100 |
| 12 Aug 2026 | 0.2100 |
| 13 May 2026 | 0.2080 |
| 11 Feb 2026 | 0.2080 |
| 12 Nov 2025 | 0.2080 |
| 13 Aug 2025 | 0.2080 |
| 14 May 2025 | 0.2050 |
| 12 Feb 2025 | 0.2050 |
| 13 Nov 2024 | 0.2050 |
| 14 Aug 2024 | 0.2050 |
| 7 May 2024 | 0.2000 |
| 13 Feb 2024 | 0.2000 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
KVUE SEC filings
13 Oct 2026
8-KSEC EDGAR
Entered a material agreement
6 Aug 2026
10-QSEC EDGAR
Quarterly report
6 Aug 2026
8-KSEC EDGAR
Results of operations
22 May 2026
8-KSEC EDGAR
Shareholder vote results
7 May 2026
10-QSEC EDGAR
Quarterly report
7 May 2026
8-KSEC EDGAR
Results of operations
15 Apr 2026
8-KSEC EDGAR
Director or officer change
8 Apr 2026
DEF 14ASEC EDGAR
Proxy statement
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.